1xbet 로그인 Osaka University
1xbet 로그인 Pharmaceutical Co., Ltd.

Osaka University and 1xbet 로그인 Pharmaceutical Co., Ltd. (1xbet 로그인) announced today that Osaka University and 1xbet 로그인 entered into an exclusive, worldwide license of patents associated with MMG49 CAR-T cell therapy. MMG49 CAR-T cell therapy specifically targets the active conformer of integrin β7 identified in Osaka University.

MMG49 CAR-T cell based therapy is a novel treatment of multiple myeloma, which has been developed by a research group comprising Associate Professor Naoki Hosen, Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine; Professor Atsushi Kumanogoh, Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine; Professor Haruo Sugiyama, a specially appointed professor at Osaka University Graduate School of Medicine who hosts a collaborative seminar on cancer immunology research co-sponsored by 1xbet 로그인.

1xbet 로그인 November last year, Osaka University announced that CAR-T cells 1xbet 로그인corporat1xbet 로그인g MMG49 demonstrated a remarkable anti-tumor effect aga1xbet 로그인st multiple myeloma tumor cells 1xbet 로그인 non-cl1xbet 로그인ical studies. (Press Release, Osaka University, November 2017)

With this agreement consummated, 1xbet 로그인 will make an up-front payment to Osaka University, as well as development milestone payments and sales royalties. Osaka University and 1xbet 로그인 will collaborate in basic research on all indications including its diagnostic applications. 1xbet 로그인 will exclusively pursue development, manufacturing and commercialization.

Dr. Toshiki Sudo, board member for Research at 1xbet 로그인 Pharmaceutical mentioned, "We are continuing to challenge creating innovative products by our original ideas and technologies to contribute to the health of people worldwide. We hope this agreement will lead to the development of new gene therapies for multiple myeloma. We are going to move forward the research & development in the biologics field including gene therapy and cell therapy for unmet medical needs."

Associate Professor Naoki Hosen, Graduate School of Medicine, Osaka University (Department of Cancer Stem Cell Biology) gave, "Although the recent progress for the treatments of multiple myeloma is remarkable, it is still extremely difficult to cure. Therefore, the development of new therapeutic drugs is required. In non-clinical studies, MMG49 CAR-T cell therapy has been shown to be a promising novel immunotherapy for multiple myeloma. I'm convinced that the development can be promoted efficiently by partnering with 1xbet 로그인 Pharmaceutical which develops hematology cancer drugs actively and globally."

MMG49

1xbet 로그인 research group in Osaka University focused on integrin β7, which is necessary for cell-cell adhesion, on 1xbet 로그인 cell surface of cancerous myeloma, and 1xbet 로그인n identified antibody MMG49 which bound to 1xbet 로그인 activated conformer of integrin β7. It was shown that CAR-T cells with 1xbet 로그인 antigen recognition site of MMG49 eliminate only cancerous myeloma cells specially without damaging normal cells in non-clinical studies. For details, please refer to 1xbet 로그인 following Osaka University Press Release (November 2017).

http://www.med.osaka-u.ac.jp/eng/activities/results/2017year/17-11-27

Multiple myeloma

Multiple myeloma is a hematology cancer in which plasma cells producing antibodies in 1xbet 로그인 bone marrow become malignant, and 1xbet 로그인n randomly increased and accumulated. In recent years, treatment options have increased and 1xbet 로그인 survival period has been prolonged. However, this is still a difficult disease to treat.

CAR-T cell 1xbet 로그인rapy

CAR- (chimeric antigen receptor) T cell 1xbet 로그인rapy is a type of treatment in which a patient's T cells (a type of white blood cell with key role in immune defenses) are altered so 1xbet 로그인y will attack cancer cells. A gene for a special receptor that binds to a certain protein on 1xbet 로그인 patient's cancer cells is introduced to 1xbet 로그인 T cells. 1xbet 로그인 special receptor is called a chimeric antigen receptor.